Rezolute, Inc.
Rezolute develops ersodetug, an antibody therapy for refractory hypoglycemia caused by hyperinsulinism.
10-KSep 24Latest SEC filing, period to Jun 30
Sep 24Latest story
September 2026
Sign inSign inRezolute develops ersodetug, an antibody therapy for refractory hypoglycemia caused by hyperinsulinism.